Bill
Bill > HR2069
summary
Introduced
04/03/2019
04/03/2019
In Committee
04/04/2019
04/04/2019
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
To amend title XI of the Social Security Act to provide for drug manufacturer price transparency. This bill requires the Centers for Medicare & Medicaid Services (CMS) to determine at least annually whether certain covered drugs under Medicare were subject to a price increase that exceeded specified thresholds. Drug manufacturers must submit justifications for such price increases to the CMS, subject to civil penalties. The bill's requirements do not apply to low-cost drugs, as identified by the CMS.
AI Summary
This bill, the Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act, aims to provide drug manufacturer price transparency. It requires the Centers for Medicare & Medicaid Services (CMS) to annually determine if certain drugs covered under Medicare experienced significant price increases above specified thresholds. If so, the drug manufacturers must submit justifications for these price increases to CMS, subject to civil penalties for noncompliance or false information. The bill does not apply to low-cost drugs, as identified by CMS based on cost or spending thresholds.
Committee Categories
Business and Industry, Health and Social Services
Sponsors (11)
Steven Horsford (D)*,
Ed Case (D),
TJ Cox (D),
Chrissy Houlahan (D),
Eleanor Holmes Norton (D),
Jamie Raskin (D),
Tom Reed (R),
Elissa Slotkin (D),
Abigail Spanberger (D),
Bryan Steil (R),
Susan Wild (D),
Last Action
Subcommittee Hearings Held. (on 05/21/2019)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/116th-congress/house-bill/2069/all-info |
| BillText | https://www.congress.gov/116/bills/hr2069/BILLS-116hr2069ih.pdf |
| Bill | https://www.congress.gov/116/bills/hr2069/BILLS-116hr2069ih.pdf.pdf |
Loading...